Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Propanolol in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18- 65~* diagnosis of stage I-III breast cancer , confirmed by a core biopsy~* Planning to undergo definitive surgery including mastectomy or breast conserving surgery~* Systolic blood pressure must be \>100 mmHg but no more than 140 mmHg and/or diastolic \> 60 mmHg and no more than 95 mmHg.~* normal baseline EKG~Exclusion criteria:~* Pregnancy; potential subjects of female bearing age will have to complete a pregnancy test during screening to ensure that they are not pregnant. Potential patients who are post-menopausal must have confirmed one year without menstrual cycle.~* Free of major medical illnesses including:~* Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)~* Uncontrolled hypertension: BP \>systolic 140/ diastolic \> 95~* Cardiac diseases (history of cardiac valve disease, coronary artery disease, congestive heart failure, A-V block, peripheral vascular disease, any cardiac arrhythmia/bradycardia) with the exception of the diagnosed cancer.~* Histories of asthma, bronchospastic disease, or obstructive pulmonary disease~* Previously diagnosed thyrotoxicosis~* Severe allergic reactions to medications which are included in the beta blocker family~* Previously or currently treated with a beta adrenergic receptor antagonist~* Patients with locally advanced or inflammatory breast cancer not amenable to surgical resection~* Patients taking any of the following medications will be excluded:~  * Drugs that are categorized as digitalis glycosides, beta-blockers and calcium channel blockers, ACE inhibitors and alpha blockers~ * Amiodarone~ * Cimetidine~ * Ciprofloxacin~ * Delavudin~ * Dobutamine~ * Ethanol~ * Fluconazole~ * Fluoxetine~ * Fluvoxamine~ * Haloperidol~ * Imipramine~ * Isoniazid~ * Isoproterenol~ * Luvoxamine~ * Paroxetine~ * Phenytoin~ * Phenobarbital.~ * Propafenone.~ * Quinidine~ * Reserpine~ * Rifampin~ * Ritonavir~ * Rizatriptan.~ * Tenioposide~ * Theophylline~ * Thyroxine~ * Tolbutamide.~ * Warfarin~ * Zileuton~ * Zolmitriptan

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- open label single arm, drug propanolol (Type: EXPERIMENTAL): all subjects will receive the experimental drug

Based on this trial design, predict the completion outcome and termination type (if applicable).